Dr. Khorana on Current Practice Patterns on Anticoagulant Treatments for Thrombosis

Alok A. Khorana, MD
Published: Thursday, Feb 04, 2016



Alok A. Khorana, MD, professor of Medicine, Department of Hematology and Oncology, Cleveland Clinic, discusses a study that examined practice patterns and patient persistence on anticoagulant treatments for cancer-associated thrombosis.

Patients with cancer are likely to develop blood clots, and there are select anticoagulant treatments available, Khorana explains, including heparin and rivaroxaban.

Khorana says that although heparin is the guideline-recommended agent to treat cancer-associated thrombosis, it is only used in approximately 25% of patients. Rivaroxaban, which is a newer agent with a broad indication, was found to also be used in only 25% of patients. Although warfarin has been used the longest and interacts with other agents, it remains to be the dominant choice of the three agents, Khorana says.



Alok A. Khorana, MD, professor of Medicine, Department of Hematology and Oncology, Cleveland Clinic, discusses a study that examined practice patterns and patient persistence on anticoagulant treatments for cancer-associated thrombosis.

Patients with cancer are likely to develop blood clots, and there are select anticoagulant treatments available, Khorana explains, including heparin and rivaroxaban.

Khorana says that although heparin is the guideline-recommended agent to treat cancer-associated thrombosis, it is only used in approximately 25% of patients. Rivaroxaban, which is a newer agent with a broad indication, was found to also be used in only 25% of patients. Although warfarin has been used the longest and interacts with other agents, it remains to be the dominant choice of the three agents, Khorana says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x